Global Gastric Cancer Market Report: 2016 Edition
Cancer is a condition where an error or mutation in the cell’s DNA occurs, causing it to grow at a rapid rate. A cancer cell continues living while a normal cell would die, thus, accumulating to form a tumor that can break off and spread throughout the body. Gastric cancer is when such a condition occurs in the stomach and has the tendency to grow through the wall of the stomach to invade nearby organs including lymph nodes and lymph vessels. There are four types of cancers of the stomach namely, Adenocarcinoma, Lymphoma, Gastrointestinal stromal tumor (GIST), Carcinoid tumor and others such as squamous cell carcinoma, small cell carcinoma, and leiomyosarcomat that can start in the stomach, but are very rare.
The causes of stomach cancer are rather unclear in medical study; however, there is a strong correlation between a diet high in smoked, salted and pickled foods, obesity and ageing. People with Helicobacter infections are also highly prone to gastric cancer. Symptoms of gastric cancer may include, fatigue, feeling bloated after eating, severe heartburn and indigestion, stomach pain, persistent and unexplained vomiting and nausea, unintentional weight loss, belching, anemia, and persistent ulcer. Its medical diagnosis techniques involve upper endoscopy, imaging tests and exploratory surgery. Treatment options include surgery, chemotherapy, radiotherapy and targeted therapy.
Global gastric cancer market is conspicuous by poor prognosis, because of the indolent nature of the disease. However, better diagnostic technology and shifting treatment market from chemotherapy to targeted therapies is expected to warrant positive growth in the years ahead. Rising oncology drug spending, ageing population, increasing obese population and rising global male population are expected to drive this growth. Certain trends in the global gastric cancer market include, a healthy pipeline of combinations targeted therapies, shifting focus towards molecular targeted therapies, and keen interest in eradication H. Pylori infection across the globe. The market is however, afflicted by certain challenges like low penetration of new targeted therapies and lack of reimbursement of cancer drugs.
The report provides an overview of the entire market through global and regional analysis. Prevalence and market value of gastric cancer across the globe and that of its various types and stages including advanced, her2 positive, stage III and metastatic gastric cancer have been analyzed.
The causes of stomach cancer are rather unclear in medical study; however, there is a strong correlation between a diet high in smoked, salted and pickled foods, obesity and ageing. People with Helicobacter infections are also highly prone to gastric cancer. Symptoms of gastric cancer may include, fatigue, feeling bloated after eating, severe heartburn and indigestion, stomach pain, persistent and unexplained vomiting and nausea, unintentional weight loss, belching, anemia, and persistent ulcer. Its medical diagnosis techniques involve upper endoscopy, imaging tests and exploratory surgery. Treatment options include surgery, chemotherapy, radiotherapy and targeted therapy.
Global gastric cancer market is conspicuous by poor prognosis, because of the indolent nature of the disease. However, better diagnostic technology and shifting treatment market from chemotherapy to targeted therapies is expected to warrant positive growth in the years ahead. Rising oncology drug spending, ageing population, increasing obese population and rising global male population are expected to drive this growth. Certain trends in the global gastric cancer market include, a healthy pipeline of combinations targeted therapies, shifting focus towards molecular targeted therapies, and keen interest in eradication H. Pylori infection across the globe. The market is however, afflicted by certain challenges like low penetration of new targeted therapies and lack of reimbursement of cancer drugs.
The report provides an overview of the entire market through global and regional analysis. Prevalence and market value of gastric cancer across the globe and that of its various types and stages including advanced, her2 positive, stage III and metastatic gastric cancer have been analyzed.
1. MARKET OVERVIEW
1.1 Introduction
1.2 Types
1.3 Stages
1.4 Causes & Prevention
1.5 Diagnosis
1.5.1 Symptoms
1.5.2 Medical Diagnosis
1.6 Treatment Options
1.6.1 Surgery
1.6.2 Chemotherapy
1.6.3 Radiotherapy
1.6.4 Targeted Therapy
2. GLOBAL MARKET
2.1 Global Gastric Cancer Market by Prevalence
2.2 Global Advanced Gastric Cancer Market by Value
3. REGIONAL MARKETS
3.1. The U.S.
3.1.1 The U.S. Gastric Cancer Market by Prevalence
3.1.2 The U.S. Her 2+ Gastric Cancer Prevalence
3.1.3 The U.S. Stage III Gastric Cancer Prevalence
3.1.4 The U.S. Advanced Gastric Cancer Market by Prevalence
3.1.5 The U.S. Advanced Gastric Cancer Market by Value
3.1.6 The U.S. Metastatic Gastric Cancer Prevalence
3.2 The European Union
3.2.1 The EU Her 2+ Gastric Cancer Prevalence
3.2.2 The EU Stage III Gastric Cancer Prevalence
3.2.3 The EU Metastatic Gastric Cancer Prevalence
3.3 The EU5
3.3.1 The EU5 Gastric Cancer Market by Prevalence
3.3.2 The EU5 Advanced Gastric Cancer Market by Prevalence
3.3.3 The EU5 Advanced Gastric Cancer Market by Value
3.4 Japan
3.4.1 Japan Gastric Cancer Market by Prevalence
3.4.2 Japan Advanced Gastric Cancer Market by Prevalence
3.4.3 Japan Advanced Gastric Cancer Market by Value
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Rising Spending on Targeted Cancer Therapies
4.1.2 Rising Oncology Drug Spending
4.1.3 Rising Ageing Population
4.1.4 Increasing Obese Population
4.1.5 Rising Global Male Population
4.1.6 Rising Cigarette Consumption
4.2 Trends
4.2.1 Combinations Targeted Therapies under Development
4.2.2 Targeted Agents in Development by Pathways
4.2.3 Shifting Focus towards Molecular Targeted Therapies
4.2.4 H. Pylori Eradication
4.3 Challenges
4.3.1 Low Penetration of New Targeted Therapies
4.3.2 Lack of Reimbursement of Cancer Drugs
5. COMPETITIVE LANDSCAPE
5.1 Global Cancer Market
5.1.1 Top Cancer Drugs Revenue Comparison
5.1.2 Potential Combination Therapy Launches
5.2 Global Gastric Cancer Market
5.2.1 Top Companies by Revenue
5.2.2 Top Companies by Revenue Growth
5.2.3 Gastric Cancer Products under Clinical Trial
6. COMPANY PROFILES
6.1 Roche Holdings AG
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Bristol Myers Squibb
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Merck & Co. Inc.
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 AstraZeneca Plc.
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
1.1 Introduction
1.2 Types
1.3 Stages
1.4 Causes & Prevention
1.5 Diagnosis
1.5.1 Symptoms
1.5.2 Medical Diagnosis
1.6 Treatment Options
1.6.1 Surgery
1.6.2 Chemotherapy
1.6.3 Radiotherapy
1.6.4 Targeted Therapy
2. GLOBAL MARKET
2.1 Global Gastric Cancer Market by Prevalence
2.2 Global Advanced Gastric Cancer Market by Value
3. REGIONAL MARKETS
3.1. The U.S.
3.1.1 The U.S. Gastric Cancer Market by Prevalence
3.1.2 The U.S. Her 2+ Gastric Cancer Prevalence
3.1.3 The U.S. Stage III Gastric Cancer Prevalence
3.1.4 The U.S. Advanced Gastric Cancer Market by Prevalence
3.1.5 The U.S. Advanced Gastric Cancer Market by Value
3.1.6 The U.S. Metastatic Gastric Cancer Prevalence
3.2 The European Union
3.2.1 The EU Her 2+ Gastric Cancer Prevalence
3.2.2 The EU Stage III Gastric Cancer Prevalence
3.2.3 The EU Metastatic Gastric Cancer Prevalence
3.3 The EU5
3.3.1 The EU5 Gastric Cancer Market by Prevalence
3.3.2 The EU5 Advanced Gastric Cancer Market by Prevalence
3.3.3 The EU5 Advanced Gastric Cancer Market by Value
3.4 Japan
3.4.1 Japan Gastric Cancer Market by Prevalence
3.4.2 Japan Advanced Gastric Cancer Market by Prevalence
3.4.3 Japan Advanced Gastric Cancer Market by Value
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Rising Spending on Targeted Cancer Therapies
4.1.2 Rising Oncology Drug Spending
4.1.3 Rising Ageing Population
4.1.4 Increasing Obese Population
4.1.5 Rising Global Male Population
4.1.6 Rising Cigarette Consumption
4.2 Trends
4.2.1 Combinations Targeted Therapies under Development
4.2.2 Targeted Agents in Development by Pathways
4.2.3 Shifting Focus towards Molecular Targeted Therapies
4.2.4 H. Pylori Eradication
4.3 Challenges
4.3.1 Low Penetration of New Targeted Therapies
4.3.2 Lack of Reimbursement of Cancer Drugs
5. COMPETITIVE LANDSCAPE
5.1 Global Cancer Market
5.1.1 Top Cancer Drugs Revenue Comparison
5.1.2 Potential Combination Therapy Launches
5.2 Global Gastric Cancer Market
5.2.1 Top Companies by Revenue
5.2.2 Top Companies by Revenue Growth
5.2.3 Gastric Cancer Products under Clinical Trial
6. COMPANY PROFILES
6.1 Roche Holdings AG
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Bristol Myers Squibb
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Merck & Co. Inc.
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 AstraZeneca Plc.
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
LIST OF CHARTS
Different Types of Gastric Cancer
Global Gastric Cancer Market by Prevalence (2015-2020E)
Global Advanced Gastric Cancer Market by Value (2015-2020E)
The U.S. Gastric Cancer Market by Prevalence (2015-2020E)
Prevalence of Her 2+ Gastric Cancer in the U.S. (2015-2020E)
Prevalence of Stage III Gastric Cancer in the U.S. (2015-2020E)
The U.S. Advanced Gastric Cancer Market by Prevalence (2015-2020E)
The U.S. Advanced Gastric Cancer Market by Value (2015-2020E)
Prevalence of Metastatic Gastric Cancer in the U.S. (2015-2020E)
Prevalence of Her2+ Gastric Cancer in the EU (2015-2020E)
Prevalence of Stage III Gastric Cancer in the EU (2015-2020E)
Prevalence of Metastatic Gastric Cancer in the EU (2015-2020E)
The EU5 Gastric Cancer Market by Prevalence (2015-2020E)
The EU5 Advanced Gastric Cancer Market by Prevalence (2015-2020E)
The EU5 Advanced Gastric Cancer Market by Value (2015-2020E)
Japan Gastric Cancer Market by Prevalence (2015E-2020E)
Japan Advanced Gastric Cancer by Prevalence (2015-2020E)
Japan Advanced Gastric Cancer Market by Value (2015-2020E)
Global Targeted Therapies Spending (2010-2015E)
Global Oncology Drug Spending by Region (2010-2015E)
Global Population Over 50 Years of Age (2010-2015E)
Global Obese Population (2010-2015E)
Global Male Population (2010-2015E)
Global Cigarettes Consumption (1910-2014)
Combination Regimen Launches in Oncology (2014-2020E)
Pipeline of Targeted Agents in Development by Pathways (2015)
Penetration of New Targeted Therapies by Country (2015)
Cancer Drugs Reimbursement Status by Country (2015E)
Potential Combination Therapy Launches by Company (2021E)
Gastric Cancer - Top Companies Revenue Comparison (2015)
Gastric Cancer - Revenue Growth Comparison by Company (2015)
Roche Holdings AG Revenue by Segment (2015)
Roche Holdings AG Revenue and Net Income (2011-2015)
Bristol Myers Revenue by Region (2015)
BMY Revenue and Net Income (2011-2015)
Merck & Co. Inc. Revenue by Segment (2015)
Merck & Co. Inc. Revenue and Net Income (2011-2015)
AstraZeneca Revenue by Region (2015)
AstraZeneca Revenue and Net Income (2011-2015)
Different Types of Gastric Cancer
Global Gastric Cancer Market by Prevalence (2015-2020E)
Global Advanced Gastric Cancer Market by Value (2015-2020E)
The U.S. Gastric Cancer Market by Prevalence (2015-2020E)
Prevalence of Her 2+ Gastric Cancer in the U.S. (2015-2020E)
Prevalence of Stage III Gastric Cancer in the U.S. (2015-2020E)
The U.S. Advanced Gastric Cancer Market by Prevalence (2015-2020E)
The U.S. Advanced Gastric Cancer Market by Value (2015-2020E)
Prevalence of Metastatic Gastric Cancer in the U.S. (2015-2020E)
Prevalence of Her2+ Gastric Cancer in the EU (2015-2020E)
Prevalence of Stage III Gastric Cancer in the EU (2015-2020E)
Prevalence of Metastatic Gastric Cancer in the EU (2015-2020E)
The EU5 Gastric Cancer Market by Prevalence (2015-2020E)
The EU5 Advanced Gastric Cancer Market by Prevalence (2015-2020E)
The EU5 Advanced Gastric Cancer Market by Value (2015-2020E)
Japan Gastric Cancer Market by Prevalence (2015E-2020E)
Japan Advanced Gastric Cancer by Prevalence (2015-2020E)
Japan Advanced Gastric Cancer Market by Value (2015-2020E)
Global Targeted Therapies Spending (2010-2015E)
Global Oncology Drug Spending by Region (2010-2015E)
Global Population Over 50 Years of Age (2010-2015E)
Global Obese Population (2010-2015E)
Global Male Population (2010-2015E)
Global Cigarettes Consumption (1910-2014)
Combination Regimen Launches in Oncology (2014-2020E)
Pipeline of Targeted Agents in Development by Pathways (2015)
Penetration of New Targeted Therapies by Country (2015)
Cancer Drugs Reimbursement Status by Country (2015E)
Potential Combination Therapy Launches by Company (2021E)
Gastric Cancer - Top Companies Revenue Comparison (2015)
Gastric Cancer - Revenue Growth Comparison by Company (2015)
Roche Holdings AG Revenue by Segment (2015)
Roche Holdings AG Revenue and Net Income (2011-2015)
Bristol Myers Revenue by Region (2015)
BMY Revenue and Net Income (2011-2015)
Merck & Co. Inc. Revenue by Segment (2015)
Merck & Co. Inc. Revenue and Net Income (2011-2015)
AstraZeneca Revenue by Region (2015)
AstraZeneca Revenue and Net Income (2011-2015)
LIST OF TABLES
Types of Targeted Therapies
Top Cancer Drugs by Revenue (2015)
Gastric Cancer Pre-Treated Clinical Trials Comparison
Gastric Cancer Treatment Naive Clinical Trials
Types of Targeted Therapies
Top Cancer Drugs by Revenue (2015)
Gastric Cancer Pre-Treated Clinical Trials Comparison
Gastric Cancer Treatment Naive Clinical Trials
